Clinical trials: Type 2 Diabetes, completed
Diabetes Mellitus, Type 2
Comparative Effectiveness of Empagliflozin in the US
Empagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, was launched as a treatment for type 2 diabetes mellitus (T2DM) in the U.S. in August 2014.
- Trial name
- NCT03363464
- Testing
- Empagliflozin, DPP-4 inhibitor, GLP-1 receptor agonist
- Where
- United States
- Volunteers
- 230,000 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes, Poor Glycemic Control
Effect of Intensive Monitoring of Patients With Poorly Controlled Type 2 Diabetes With Different Glycemic Background
In Turkey, only 55% of patients with type 2 diabetes have been diagnosed, and 91% of these patients have been receiving treatment. The rate of patients reaching the treatment target is 50%.
- Trial name
- NCT06385899
- Where
- Turkey (Türkiye)
- Volunteers
- 266 people
- Sponsor
- Goztepe Prof Dr Suleyman Yalcın City Hospital
Type 2 Diabetes Mellitus (T2DM)
Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy Volunteers
This study is a randomized, open-label, single dose, crossover study to evaluate the food effect of CKD-383 in healthy volunteers
- Trial name
- CKD-383 FDI P1 (NCT06695598)
- Testing
- CKD-383
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetic Neuropathies
Effect of Ankle Proprioception Training in Type 2 Diabetic Neuropathy
Diabetes mellitus is a metabolic disease described by hyperglycemia, which results from deficiencies in insulin secretion, the action of insulin on the target tissue, both.
- Trial name
- NCT05190198
- Testing
- Proprioceptive neuromuscular facilitation, conventional therapy
- Where
- Pakistan
- Volunteers
- 46 people
- Sponsor
- Riphah International University
Diabetes Mellitus, Type 2
Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
This study aims to determine if the addition of Canagliflozin (Invokana™) therapy to monotherapy of metformin is more effective at achieving the double composite endpoint of a reduction in HbA1c (≥ 0.3%) and weight loss (≥1kg)…
- Trial name
- Can Do (NCT02694263)
- Testing
- Canagliflozin, Repaglinide, Pioglitazone
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Leicester
Diabetes Mellitus, Type 2
A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools
This study will compare four different semaglutide versions and different injection tools. The study aims to show similar levels of semaglutide in the blood using different versions of semaglutide.
- Trial name
- NCT03598621
- Testing
- Semaglutide, 0.5 mg/mL, Semaglutide, 1.0 mg/mL, Semaglutide, 1.34 mg/mL
- Where
- 2 sites in Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hypertension, Type 2 Diabetes Mellitus
Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
Various guidelines recommended angiotensin converting enzyme (ACE) inhibitors or angiotensin Ⅱ receptor-1 blockers (ARBs) for hypertensive patients with diabetes on the basis of the cardiac- and reno-protective effects of these…
- Trial name
- NCT00129233
- Testing
- Valsartan, Amlodipine
- Where
- Japan
- Volunteers
- 1,150 people
- Sponsor
- Nagoya University
Type 2 Diabetes Mellitus
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a specific metabolite (which is a marker of in vivo…
- Trial name
- NCT00618995
- Testing
- Comparator: ER niacin (+) laropiprant, Comparator: ER niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets
Randomized, Single Oral Dose, Two-period, Two Sequence, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin-Linagliptin-Metformin XR Tablet 25mg/ 5mg/1000mg (25mg Empagliflozin /5mg Linagliptin /1000mgMetformin…
- Trial name
- NCT07213895
- Testing
- Empagliflozin/Linagliptin/Metformin HCL, Trijardy® XR Extended release film coated tablets
- Where
- Jordan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Heart Failure, Type 2 Diabetes Mellitus
SGLT2 Inhibition in Combination With Diuretics in Heart Failure
The RECEDE-CHF trial is a single centre phase IV, randomised, double-blind, placebo-controlled, crossover trial conducted in NHS Tayside, Scotland comparing empagliflozin 25mg, to placebo in patients with Type 2 Diabetes and mild…
- Trial name
- RECEDE-CHF (NCT03226457)
- Testing
- Empagliflozin 25mg, Frusemide
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Dundee
Type2 Diabetes
Cardio-metabolic and Inflammatory Impact of Starch Digestibility in Type 2 Diabetic Patients
This is a monocentric, randomized, single-blind and controlled study with a parallel design (2 arms). The research hypothesis is that the diet high in Slow Digestible Starch (SDS) content (H-SDS) will lower the daylong glycemic…
- Trial name
- NCT03847701
- Testing
- Balanced diet high in Slowly Digestible Starch, Balanced diet low in Slowly Digestible Starch
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Mondelēz International, Inc.
Type 2 Diabetes Mellitus
Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and glimepiride as monotherapy
- Trial name
- NCT00363519
- Testing
- Sitagliptin phosphate
- Where
- 8 sites in Japan
- Volunteers
- 195 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Type 1 Diabetes
Genome-wide Association Study of Different Types of Diabetes and Construction of Genetic Risk Score
To enhance the genetic profile of T1D patients in China and construct a Chinese-specific GRS and evaluated its ability to differentiate between T1D and controls, as well as between T1D and T2D.
- Trial name
- NCT06791330
- Volunteers
- 7,000 people
- Sponsor
- Second Xiangya Hospital of Central South University
Atherosclerosis, Type 2 Diabetes
High-sensitivity C-reactive Protein and United Kingdom Prospective Diabetes Study (UKPDS) Risk Score in Type 2 Diabetes
The UKPDS risk score is recommended to assess global risk for future coronary heart disease (CHD) events in primary prevention. Recently, high-sensitivity C-reactive protein (hsCRP) has emerged as a strong independent risk factor…
- Trial name
- NCT01099865
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Korea University
Diabetes Mellitus, Type 2, Healthy Males
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
26 subjects will be enrolled into 5 different dose groups. The trial will consist of a screening, a dosing and a follow-up visit.
- Trial name
- NCT00475371
- Testing
- MKC253 Inhalation Powder
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Type 2 Diabetes
Long-term Study of KAD-1229 in Type 2 Diabetes Patients
The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show inadequate glycemic control with diet, and…
- Trial name
- NCT01333592
- Testing
- KAD-1229
- Where
- Japan
- Volunteers
- 136 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Diabetic Neuropathies, Peripheral Nervous System Diseases
Effect of Physical Therapy in Improving the Health of Patients With Diabetic Peripheral Neuropathy
People with diabetes can have nerve damage in their extremities (peripheral neuropathy), and this can lead them to being less able to maintain their balance when they are standing, walking or performing complex movement tasks in…
- Trial name
- DPN-QoL (NCT02115932)
- Testing
- Strength & Balance Training
- Where
- Singapore
- Volunteers
- 143 people
- Sponsor
- National University Health System, Singapore
Treatment Adherence
Colchicine Has Anti-diabetic Effect
Colchicine has antidiabetic effect and may be an option for type 2 diabetes management
- Trial name
- NCT04377321
- Testing
- Colchicine Tablets
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Ministry of Health and Population, Egypt
Diabetes Mellitus, Type 2
A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus
This is a double blind, randomised, placebo controlled, single dose escalation, first-time-in-human, 5-way crossover study to assess the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of ascending doses of…
- Trial name
- NCT01571661
- Testing
- GSK189075A
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
Reduced factorial design study with 24 week randomized treatment of initial combination therapy with linagliptin and metformin in T2DM patients
- Trial name
- NCT01708902
- Testing
- linagliptin2.5mg/metformin1000mg, linagliptin 5mg, Metformin 500mg
- Where
- 56 sites in China, Malaysia and 2 more
- Volunteers
- 876 people
- Sponsor
- Boehringer Ingelheim
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.